Active Penny Stocks in the News
PennyTrader.com presents a range of the hottest penny stocks on the OTC and OTCBB market today. In addition to daily hot stock alerts, PennyTrader.com‘s new penny stock alert service is fast becoming the premier stock alert list to be on.
Subscribe to our FREE penny stock email alert service by visiting http://www.pennytrader.com/sign-up/
Pervasip Corp. (OTCBB: PVSP) reached up 88.89% in morning trading to $.17 with 100K shares traded. Pervasip Corp. (OTCBB:PVSP.ob - News), a provider of cloud-based communications solutions, applications and services, today announced that for the fourth time, its lender has cancelled warrants to purchase 2.5 million shares of Pervasip common stock. The lender has agreed to cancel warrants to purchase 2.5 million shares of Pervasip common stock for each $50,000 of equity injected by an investor group, until all warrants are canceled upon the receipt of $300,000 in total. As of today, warrants to purchase 10 million shares of Pervasip common stock have been cancelled in total, and warrants to purchase 5.9 million shares remain outstanding.
For detailed quote and full article http://www.pennytrader.com/quotes/PVSP.php
AspenBio Pharma, Inc. (NASDAQ: APPY) reached up 52.23% in morning trading to $.8677 with 2M shares traded. AspenBio Pharma, Inc. is developing and commercializing innovative products that address unmet diagnostic and therapeutic needs. AspenBio Pharma, Inc. (NASDAQ:APPY - News) today announced that the Company has initiated manufacturing of its AppyScore™ cassette-based test system to be used in further validation and verification testing of AppyScore -- a novel, blood-based diagnostic test designed to aid emergency department physicians in the difficult challenge of evaluating patients suspected of having appendicitis. Initial pre-clinical market testing is anticipated to commence prior to the end of the fiscal year. In addition, the Company reported that it has made key additions to its team to support AppyScore's clinical development, regulatory submission and market launch planning. Aspen has contracted with Michael Wandell, PharmD to lead its human diagnostic products' clinical and regulatory strategy, including taking over primary responsibility for clinical validation study design and ongoing communications with the US Food and Drug Administration, and Erik Miller to spearhead commercial planning efforts, including pre-clinical field testing of the AppyScore system.
For detailed quote and full article http://www.pennytrader.com/quotes/APPY.php
SuperGen, Inc. (NASDAQ: SUPG) reached up 19.31% in morning trading to $2.78 with 2M shares traded. SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. SuperGen, Inc. (NASDAQ:SUPG - News) yesterday reported financial results for the third quarter and nine months ended September 30, 2010.
For detailed quote and full article http://www.pennytrader.com/quotes/SUPG.php
Subscribe to our FREE penny stock email alert service by visiting http://www.pennytrader.com/sign-up/
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report
For complete disclosure information go to http://www.pennytrader.com/disclosure/
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to http://www.pennytrader.com/disclaimer/
